Mycophenolate sodium treatment in patients with primary Sjögren syndrome: a pilot trial

The aim of this study was to evaluate the efficacy and safety of mycophenolate sodium (MPS) in patients with primary Sjögren syndrome (pSS) refractory to other immunosuppressive agents. Eleven patients with pSS were treated with MPS up to 1,440 mg daily for an observation period of 6 months in this...

Descripción completa

Detalles Bibliográficos
Autores principales: Willeke, Peter, Schlüter, Bernhard, Becker, Heidemarie, Schotte, Heiko, Domschke, Wolfram, Gaubitz, Markus
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246233/
https://www.ncbi.nlm.nih.gov/pubmed/17986340
http://dx.doi.org/10.1186/ar2322

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246233/
https://www.ncbi.nlm.nih.gov/pubmed/17986340
http://dx.doi.org/10.1186/ar2322

Ejemplares similares